慢性乙型肝炎抗病毒治疗适应证的变迁

刘津津; 张梦阳; 孙亚朦; 尤红

doi:10.3969/j.issn.1001-5256.2023.06.007

慢性乙型肝炎抗病毒治疗适应证的变迁

DOI: 10.3969/j.issn.1001-5256.2023.06.007

首都医科大学附属北京友谊医院，北京 100050

基金项目:

北京市科学技术委员会“首都临床特色诊疗技术研究及转化应用”专项 (Z221100007422115)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：刘津津负责整理文献及撰写；张梦阳、孙亚朦负责论文修订；尤红负责论文终审。

详细信息

通信作者:
尤红，youhong30@sina.com (ORCID：0000-0001-9409-1158)

计量
- 文章访问数: 630
- HTML全文浏览量: 93
- PDF下载量: 210
- 被引次数: 0
出版历程
- 收稿日期: 2023-04-01
- 录用日期: 2023-05-01
- 出版日期: 2023-06-20

Evolution in the indications for anti-viral therapy in chronic hepatitis B

Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research funding:

Beijing Municipal Science & Technology Commission (Z221100007422115)

More Information

Corresponding author: YOU Hong, youhong30@sina.com (ORCID: 0000-0001-9409-1158)

摘要

摘要: 为减轻慢性乙型肝炎(CHB)相关疾病负担，提高CHB治疗率，2005—2022年中华医学会发布的《慢性乙型肝炎防治指南》中，抗病毒适应证呈逐渐放宽、简化的趋势。本文旨从HBeAg阳性和阴性CHB抗病毒适应证的趋同、HBV DNA治疗阈值的降低、血清丙氨酸转氨酶治疗阈值的降低、对疾病进展风险因素的重视，以及肝硬化患者病毒学指标要求逐步放宽五个方面来阐述CHB抗病毒治疗适应证的变迁。
- 乙型肝炎, 慢性 /
- 抗病毒治疗 /
- 适应证
Abstract: In order to reduce the disease burden of chronic hepatitis B (CHB) and improve the treatment rate of CHB, the indications for anti-viral therapy have been gradually expanded and simplified in guidelines for the prevention and treatment of CHB released by Chinese Medical Association from 2005 to 2022. This article elaborates on the evolution in the indications for anti-viral therapy in CHB from the five aspects of converging indications of HBeAg-positive and HBeAg-negative CHB, reduction in the treatment threshold of HBV DNA, reduction in the treatment threshold of serum alanine aminotransferase, emphasis on the risk factors for disease progression, and gradual loosening of the requirements for virological indicators in patients with liver cirrhosis.
- Hepatitis B, Chronic /
- Anti-Viral Treatment /
- Treatment Indication

HTML全文

参考文献(30)

[1]	Polaris observatory HBV collaborators[EB/OL]. [2022-11-10]. http://cdafound.org/dashboard/polaris/dashboard.html.
[2]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. J Clin Hepatol, 2006, 22(1): 3-15. http://lcgdbzz.org/article/id/LCGD200601000 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 临床肝胆病杂志, 2006, 22(1): 3-15. http://lcgdbzz.org/article/id/LCGD200601000
[3]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J]. J Clin Hepatol, 2011, 27(1): 113-128. http://lcgdbzz.org/article/id/LCGD201101035 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 临床肝胆病杂志, 2011, 27(1): 113-128. http://lcgdbzz.org/article/id/LCGD201101035
[4]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[5]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[6]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association; Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)[J]. Chin J Infect Dis, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
[7]	YENILMEZ E, ÇETINKAYA RA, TURAL E. Diagnostic dilemma for low viremia with significant fibrosis; is hepatitis B virus DNA threshold level a good indicator for predicting liver damage?[J]. Balkan Med J, 2018, 35(4): 326-332. DOI: 10.4274/balkanmedj.2017.0888.
[8]	JENG WJ, PAPATHEODORIDIS GV, LOK A. Hepatitis B[J]. Lancet, 2023, 401(10381): 1039-1052. DOI: 10.1016/S0140-6736(22)01468-4.
[9]	ZHANG Q, PENG H, LIU X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease[J]. J Clin Transl Hepatol, 2021, 9(6): 850-859. DOI: 10.14218/JCTH.2021.00046.
[10]	LEE MH, YANG HI, LIU J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles[J]. Hepatology, 2013, 58(2): 546-554. DOI: 10.1002/hep.26385.
[11]	ZHAO Q, LIU K, ZHU X, et al. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase[J]. Antiviral Res, 2020, 184: 104953. DOI: 10.1016/j.antiviral.2020.104953.
[12]	SHANG H, CHEN WX, PAN BS, et al. Reference intervals for common tests of liver function, electrolytes and blood cell analysis of Chinese adults[J]. Chin J Lab Med, 2013, 36(5): 393-394. DOI: 10.3760/cma.j.issn.1009-9158.2013.05.003. 尚红, 陈文祥, 潘柏申, 等. 中国成人常用肝功能和电解质及血细胞分析项目参考区间[J]. 中华检验医学杂志, 2013, 36(5): 393-394. DOI: 10.3760/cma.j.issn.1009-9158.2013.05.003.
[13]	WU Z, MA AL, XIE Q, et al. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101463. DOI: 10.1016/j.clinre.2020.05.011.
[14]	DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.
[15]	KAO JH, HU TH, JIA J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B[J]. Aliment Pharmacol Ther, 2020, 52(10): 1540-1550. DOI: 10.1111/apt.16097.
[16]	SARRI G, WESTBY M, BERMINGHAM S, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance[J]. BMJ, 2013, 346: f3893. DOI: 10.1136/bmj.f3893.
[17]	TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
[18]	Chinese Society of Infectious Diseases, Chinese Medical Association. Expert opinion on expanding anti-HBV treatment for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060. 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
[19]	WANG H, SHAN S, YOU H, et al. Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B[J]. J Clin Hepatol, 2022, 38(6): 1269-1274. DOI: 10.3969/j.issn.1001-5256.2022.06.011. 王皓, 单姗, 尤红, 等. 抗病毒治疗适应证变化对提高慢性乙型肝炎治疗率的影响[J]. 临床肝胆病杂志, 2022, 38(6): 1269-1274. DOI: 10.3969/j.issn.1001-5256.2022.06.011.
[20]	ZHANG S, WANG C, LIU B, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation[J]. Lancet Reg Health West Pac, 2023: 100738. DOI: https://doi.org/ 10.1016/j.lanwpc.2023.100738.
[21]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[22]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[23]	SUN Y, CHANG J, LIU X, et al. Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis[J]. BMJ Open, 2019, 9(11): e029793. DOI: 10.1136/bmjopen-2019-029793.
[24]	YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
[25]	CHAYANUPATKUL M, OMINO R, MITTAL S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection[J]. J Hepatol, 2017, 66(2): 355-362. DOI: 10.1016/j.jhep.2016.09.013.
[26]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004. 中华医学会感染病学分会, 中华医学会肝病学分会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
[27]	SINN DH, KIM SE, KIM BK, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019, 26(12): 1465-1472. DOI: 10.1111/jvh.13185.
[28]	ALSHUWAYKH O, DAUGHERTY T, CHEUNG A, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy[J]. Hepatol Commun, 2022, 6(11): 3052-3061. DOI: 10.1002/hep4.2064.
[29]	RAZAVI-SHEARER D, ESTES C, GAMKRELIDZE I, et al. Cost-effectiveness analysis of treating all HBsAg plus individuals in the United States[J]. Hepatology, 2021, 74(Suppl 1): 30A. DOI: 10.1002/hep.32187.
[30]	WONG RJ, KAUFMAN HW, NILES JK, et al. Simplifying treatment criteria in chronic hepatitis B: Reducing barriers to elimination[J]. Clin Infect Dis, 2023, 76(3): e791-e800. DOI: 10.1093/cid/ciac385.